RegCell, a biotechnology company developing novel therapies for autoimmune diseases by leveraging the natural biology of regulatory T cells (Tregs) with its next-generation cell reprogramming platform, today announced the appointment of Michael V. McCullar, Ph.D., MBA as its new President, Chief Executive Officer, and Representative Director.
